Claims:

1. An anti-idiotypic antibody fused to albumin or a functional fragment of albumin~~,~~

~~2. The anti-idiotypic antibody albumin fusion according to claim 1,~~ wherein the anti-idiotypic antibody is specific for an anti-CD38 antibody having a variable heavy chain ~~-~~domain ~~-~~comprising the amino acid sequence ~~QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (~~of SEQ ID NO: 7~~)~~, and a variable light chain domain comprising the amino acid sequence ~~DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (~~of SEQ ID NO: 8~~)~~, and wherein the anti-idiotypic antibody is a Fab fragment.

~~3~~2. The anti-idiotypic antibody albumin fusion according to ~~any one of the preceding claims~~claim 1, wherein said anti-idiotypic antibody comprises a variable heavy chain comprising an HCDR1 of the amino acid sequence ~~YSFSNYWIS (~~of SEQ ID NO: 18~~)~~, an HCDR2 of the amino acid sequence ~~WMGIIDPASSKTRYSPSFQG (~~of SEQ ID NO: 19~~)~~, an HCDR3 of the amino acid sequence ~~SRGAGMDY (~~of SEQ ID NO: 20~~)~~, and a variable light chain comprising an LCDR1 of the amino acid sequence ~~TGSSSNIGAGYDVH (~~of SEQ ID NO: 21~~)~~, an LCDR2 of the amino acid sequence ~~LLIYADNNRPS (~~of SEQ ID NO: 22~~)~~, an LCDR3 of the amino acid sequence ~~GSYDESSNSM (~~of SEQ ID NO: 23~~)~~.

43. The anti-idiotypic antibody fused to albumin fusion according to any one of the preceding claims, wherein

said anti-idiotypic antibody comprises the variable heavy chain of the amino acid sequence QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWISWVRQMPGKGLEWMGIIDPASSKTRYSPSFQGQVTISADKS ISTAYLQWSSLKASDTAMYYCARSRGAGMDYWGQGTLVTVSS (of SEQ ID NO: 16), and the variable light chain of the amino acid

sequence DIVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYADNNRPSGVPDRFSGSK SGTSASLAITGLQSEDEADYYCGSYDESSNSMVFGGGTKLTVLGQ (of SEQ ID NO: 17).

54. The anti-idiotypic antibody fused to albumin fusion according any one of the preceding claims, wherein thecomprising a

heavy chain comprises comprising the heavy chain amino acid sequence QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWISWVRQMPGKGLEWMGIIDPASSKTRYSPSFQGQVTISADKS ISTAYLQWSSLKASDTAMYYCARSRGAGMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSDIDAHKS EVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLR ETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEV SKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAAD FVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEP QNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQ LCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKP KATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGLVNSRHHHHHH (of SEQ ID NO: 24), and

~~wherein the~~a

light chain ~~comprises~~ comprising the light chain amino acid sequence

~~DIVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYADNNRPSGVPDRFSGSKSGTSASLA~~

~~ITGLQSEDEADYYCGSYDESSNSMVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVA~~

~~WKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS~~ (of SEQ ID NO: 25~~)~~.

5. The monoclonal anti-idiotypic antibody fused to albumin according to claim 1, wherein the anti-idiotypic antibody is an IgG1 isotype.

6. The monoclonal anti-idiotypic antibody fused to albumin according to claim 1, wherein the anti-idiotypic antibody is an IgM isotype.

7. The monoclonal anti-idiotypic antibody fused to albumin according to claim 1, wherein the albumin is a human albumin having the amino acid sequence of SEQ ID NO: 6.

~~6~~8. The anti-idiotypic antibody fused to albumin ~~fusion~~ according any one of the preceding claims for use in

evaluating a blood sample.

~~7~~9. A nucleic acid encoding the anti-idiotypic antibody fused to albumin ~~fusion~~ according to any one of the

preceding claims.

~~8~~10. A method of evaluating a blood sample obtained from a patient undergoing treatment for multiple

myeloma or other gammopathy comprising

a) obtaining a blood sample from said patient,

b) incubating the blood sample with an anti-idiotypic antibody fused to albumin ~~fusion~~ according to any

one ~~-~~of claims 1-~~7~~8,

c) performing immunofixation electrophoresis (IFE), and

d) reporting the results of the IFE,

where the sample is evaluated for total M-protein levels, and

~~-~~wherein the patient is undergoing treatment with the anti-CD38 antibody

having a variable heavy chain domain comprising the amino acid sequence ~~QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (~~of SEQ ID NO: 7~~)~~, and a variable light chain domain comprising the amino acid sequence ~~DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGN TATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (~~of SEQ ID NO: 8~~)~~.

~~9~~11. An anti-idiotypic antibody that is specific for an anti-CD38 antibody having a variable heavy chain domain comprising the amino acid sequence ~~QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (~~of SEQ ID NO: 7~~)~~, and a variable light chain domain comprising the amino acid sequence ~~DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGN TATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (~~of SEQ ID NO: 8~~)~~,

~~10. A method of evaluating a blood sample obtained from a patient undergoing treatment for multiple myeloma or other gammopathy comprising~~

~~a) obtaining a blood sample from said patient,~~

~~b) incubating the blood sample with an anti-idiotypic antibody specific for the anti-CD38 antibody having a variable heavy domain comprising the amino acid sequence QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 7), and a variable light chain domain comprising the amino acid sequence DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 8),~~

~~c) performing immunofixation electrophoresis (IFE), and~~

~~d) reporting the results of the IFE,~~

~~wherein the patient is undergoing treatment with the anti-CD38 antibody having a variable heavy domain comprising the amino acid sequence QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 7), and a variable light chain domain comprising the amino acid sequence DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGT QAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 8),~~

~~where the sample is evaluated for total M-protein levels.~~

~~11. The antibody according to claim 9 or method according to claim 10,~~ and~~,~~ wherein said anti-idiotypic antibody comprises a variable heavy chain comprising

an HCDR1 of the amino acid sequence ~~YSFSNYWIS (~~of SEQ ID NO: 18~~)~~, ~~26~~

an HCDR2 of the amino acid sequence ~~WMGIIDPASSKTRYSPSFQG (~~of SEQ ID NO: 19~~)~~,

an HCDR3 of the amino acid sequence ~~SRGAGMDY (~~of SEQ ID NO: 20~~)~~, and

a variable light chain comprising

an LCDR1 of the amino acid sequence ~~TGSSSNIGAGYDVH (~~of SEQ ID NO: 21~~)~~,

an LCDR2 of the amino acid sequence ~~LLIYADNNRPS (~~of SEQ ID NO: 22~~)~~,

an LCDR3 of the amino acid sequence ~~GSYDESSNSM (~~of SEQ ID NO: 23~~)~~.